According to a recent LinkedIn post from RECEPTORAI, the company plans to attend the TIDES: Oligonucleotides and Peptide Therapeutics USA 2026 conference in Boston from May 11 to 14. The post notes that CEO and Founder Alan Nafiev, Ph.D., and Head of Business Development Askar Kuchumov, Ph.D., intend to connect with teams focused on peptide therapeutics, AI-driven drug discovery, and computational optimization.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights discussion topics such as membrane permeability modeling, gastrointestinal permeability optimization, and multi-objective optimization aimed at designing orally deliverable therapeutic peptides. For investors, this suggests a strategic effort to position RECEPTORAI within specialized networks in peptide and AI-enabled drug discovery, potentially expanding its partnership pipeline and reinforcing its relevance in computational biology-driven therapeutics.